| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Borgeson Blake | Director | C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY | /s/ Jonathan Golightly, attorney-in-fact | 04 Mar 2026 | 0001856094 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RXRX | Class A Common Stock | Sale | $588,200 | -170,000 | -2.6% | $3.46 | 6,259,863 | 03 Mar 2026 | Direct |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).